Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 1300 participants.

Also called NCT04474223

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04474223
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04474223. Allocation not applicable; no masking; primary purpose treatment. Start 2020-08-01 (actual); primary completion 2028-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
Condition
AVB - Atrioventricular Block
Condition
Fetal AVB
Intervention (Drug)
Dexamethasone
Intervention (Drug)
IVIG
Lead sponsor
NYU Langone Health (class: other)

Record details

Record id
cardio:ct-nct04474223
Content hash
28ab77f6c8856253ca55f65af637ef0a390e328817764e5dcdcf3b8f5e98e2f4